Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$142.50 -0.9%	$135.01	$110.04 ▼ $200.37	$20.89B	0.11	1.62 million shs	3.75 million shs
BMRN BioMarin Pharmaceutical	$54.36 -1.4%	$57.60	$52.93 ▼ $73.51	$10.44B	0.35	1.90 million shs	4.99 million shs
INCY Incyte	$86.53 +0.6%	$80.18	$53.56 ▼ $87.99	$16.90B	0.75	1.79 million shs	5.48 million shs
UTHR United Therapeutics	$417.57 +1.9%	$329.55	$266.98 ▼ $436.95	$18.84B	0.62	951,732 shs	1.94 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-1.63%	+2.29%	+14.22%	-28.52%
BMRN BioMarin Pharmaceutical	0.00%	+0.50%	-7.20%	+0.52%	-23.10%
INCY Incyte	0.00%	+4.13%	+1.75%	+28.65%	+31.62%
UTHR United Therapeutics	0.00%	+3.10%	+33.74%	+45.80%	+18.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$142.50 -0.9%	$135.01	$110.04 ▼ $200.37	$20.89B	0.11	1.62 million shs	3.75 million shs
BMRN BioMarin Pharmaceutical	$54.36 -1.4%	$57.60	$52.93 ▼ $73.51	$10.44B	0.35	1.90 million shs	4.99 million shs
INCY Incyte	$86.53 +0.6%	$80.18	$53.56 ▼ $87.99	$16.90B	0.75	1.79 million shs	5.48 million shs
UTHR United Therapeutics	$417.57 +1.9%	$329.55	$266.98 ▼ $436.95	$18.84B	0.62	951,732 shs	1.94 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-1.63%	+2.29%	+14.22%	-28.52%
BMRN BioMarin Pharmaceutical	0.00%	+0.50%	-7.20%	+0.52%	-23.10%
INCY Incyte	0.00%	+4.13%	+1.75%	+28.65%	+31.62%
UTHR United Therapeutics	0.00%	+3.10%	+33.74%	+45.80%	+18.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.32	Hold	$181.65	27.48% Upside
BMRN BioMarin Pharmaceutical	2.64	Moderate Buy	$92.60	70.35% Upside
INCY Incyte	2.33	Hold	$82.53	-4.62% Downside
UTHR United Therapeutics	2.69	Moderate Buy	$438.85	5.10% Upside

Current Analyst Ratings Breakdown

Latest BMRN, BIIB, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/19/2025	INCY Incyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$115.00 ➝ $118.00
9/10/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$405.00 ➝ $525.00
9/8/2025	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$60.00
9/5/2025	UTHR United Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$510.00 ➝ $575.00
9/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$400.00 ➝ $500.00
9/4/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$415.00 ➝ $560.00
9/4/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/4/2025	INCY Incyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $104.00
9/3/2025	BMRN BioMarin Pharmaceutical	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$85.00
9/3/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$295.00 ➝ $414.00

(Data available from 9/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.16	$23.10 per share	6.17	$114.71 per share	1.24
BMRN BioMarin Pharmaceutical	$3.06B	3.41	$3.25 per share	16.75	$29.69 per share	1.83
INCY Incyte	$4.58B	3.69	$0.55 per share	156.30	$17.90 per share	4.83
UTHR United Therapeutics	$2.88B	6.55	$28.39 per share	14.71	$144.34 per share	2.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.46	13.62	8.63	1.12	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$3.37	16.13	12.47	0.69	21.45%	12.59%	10.13%	11/4/2025 (Estimated)
INCY Incyte	$32.62M	$4.40	19.67	13.23	0.68	18.99%	21.99%	14.43%	11/4/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.62	16.30	15.19	6.37	40.36%	18.73%	16.49%	10/29/2025 (Estimated)

Latest BMRN, BIIB, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.80	$6.41	-$0.39	$6.41	$802.13 million	$798.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.36	2.50	1.79
BMRN BioMarin Pharmaceutical	0.10	5.56	3.60
INCY Incyte	0.01	2.85	2.78
UTHR United Therapeutics	N/A	7.26	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
BMRN BioMarin Pharmaceutical	0.85%
INCY Incyte	17.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	192.02 million	190.38 million	Optionable
INCY Incyte	2,617	195.28 million	160.52 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

BMRN, BIIB, UTHR, and INCY Headlines

Recent News About These Companies

Wedge Capital Management L L P NC Has $27.54 Million Holdings in United Therapeutics Corporation $UTHR

September 21 at 9:37 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,467,870.00 in Stock

September 21 at 4:23 AM | americanbankingnews.com

Pallas Capital Advisors LLC Has $527,000 Stock Holdings in United Therapeutics Corporation $UTHR

September 21 at 3:44 AM | marketbeat.com

Judy Olian Sells 1,800 Shares of United Therapeutics (NASDAQ:UTHR) Stock

September 20 at 5:46 PM | marketbeat.com

United Therapeutics Corporation $UTHR Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

September 20 at 5:58 AM | marketbeat.com

Director’s Major Stock Sale at United Therapeutics!

September 19 at 10:11 PM | tipranks.com

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

September 19 at 6:47 PM | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

September 19 at 5:31 PM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,467,870.00 in Stock

September 19 at 5:31 PM | marketbeat.com

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized TyvasoÂ® in Idiopathic Pulmonary Fibrosis

September 19 at 8:01 AM | businesswire.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

September 19 at 6:59 AM | insidertrades.com

Signal Advisors Wealth LLC Invests $1.53 Million in United Therapeutics Corporation $UTHR

September 19 at 4:16 AM | marketbeat.com

Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

September 18, 2025 | marketbeat.com

Balefire LLC Invests $376,000 in United Therapeutics Corporation $UTHR

September 18, 2025 | marketbeat.com

Livforsakringsbolaget Skandia Omsesidigt Trims Holdings in United Therapeutics Corporation $UTHR

September 18, 2025 | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

September 17, 2025 | insidertrades.com

Voya Investment Management LLC Boosts Stock Position in United Therapeutics Corporation $UTHR

September 17, 2025 | marketbeat.com

United Therapeutics management to meet with Cantor Fitzgerald

September 16, 2025 | msn.com

Liquidia Corporation (LQDA): A Bull Case Theory

September 16, 2025 | uk.finance.yahoo.com

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

September 16, 2025 | pharmiweb.comP

Swedbank AB Decreases Stock Position in United Therapeutics Corporation $UTHR

September 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMRN, BIIB, UTHR, and INCY Company Descriptions

Biogen NASDAQ:BIIB

$142.50 -1.31 (-0.91%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$142.28 -0.22 (-0.16%)

As of 08:54 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$54.36 -0.78 (-1.41%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$55.14 +0.78 (+1.43%)

As of 08:51 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Incyte NASDAQ:INCY

$86.53 +0.53 (+0.62%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$86.75 +0.22 (+0.25%)

As of 08:49 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$417.57 +7.70 (+1.88%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$409.00 -8.57 (-2.05%)

As of 08:54 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRN, BIIB, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRN, BIIB, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRN, BIIB, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMRN, BIIB, UTHR, and INCY Company Descriptions

Biogen NASDAQ:BIIB

BioMarin Pharmaceutical NASDAQ:BMRN

Incyte NASDAQ:INCY

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRN, BIIB, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRN, BIIB, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRN, BIIB, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMRN, BIIB, UTHR, and INCY Company Descriptions

Biogen NASDAQ:BIIB

BioMarin Pharmaceutical NASDAQ:BMRN

Incyte NASDAQ:INCY

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools